- P-ISSN 1010-0695
- E-ISSN 2288-3339
- Log In/Sign Up
- P-ISSN1010-0695
- E-ISSN2288-3339
Article Detail
Home > Article Detail
Lonicerae Flos Inhibits Cigarette-induced Lung Inflammatory Responses in Animal Model of Chronic Obstructive Pulmonary Disease
Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2013, v.34 no.2, pp.10-19
&
(2013). Lonicerae Flos Inhibits Cigarette-induced Lung Inflammatory Responses in Animal Model of Chronic Obstructive Pulmonary Disease. Journal of Korean Medicine, 34(2), 10-19.
- Downloaded
- Viewed
Abstract
Objectives: In the present study, we evaluate the anti-inflammatory effect of Lonicerae Flos on cigarette-induced lung inflammatory responses in animal model of chronic obstructive pulmonary diseases (COPD). Methods: To inspect the effects of Lonicerae Flos, we evaluated Lonicerae Flos functions in vivo including immune cell profiles in bronchoalveolar lavage (BAL) fluid, cytokine production and tissue morphological changes. Results: Lonicerae Flos significantly inhibited immune cell infiltrations into the BAL fluid (neutrophils, macrophages, lymphocytes). TNF-α, and interleukin-6 (IL-6) were substantially decreased in the BAL fluid of Lonicerae Flos-treated mice compared with cigarette-exposed control mice. In addition, the hypertrophy of goblet cells in the epithelial cells was reduced in both Lonicerae Flos- and roflumilast-treated mice. Conclusions: The results of this study provide evidence that treatment with Lonicerae Flos exerts strong therapeutic effects against cigarette-induced lung inflammation in vivo. Therefore, this herbal medicine may represent a novel therapeutic agent for lung inflammation in general, as well as a specific agent for the treatment of COPD.
- keywords
- COPD, cigarette, Lonicerae Flos, neutrophil, IL-6, TNF-α
Reference
1
1. Halbert RJ, Natoli JL, Gano A, Badamgarav E,Buist AS, Mannino DM. Global burden ofCOPD: systematic review and meta-analysis. EurRespir J. 2006;28(3):523-32.
2
2. Barnes PJ. Immunology of asthma and chronicobstructive pulmonary disease. Nat RevImmunol. 2008;8(3):183-92.
3
3. Fabbri L, Pauwels RA, Hurd SS. Global Strategyfor the Diagnosis, Management, and Preventionof Chronic Obstructive Pulmonary Disease:GOLD Executive Summary updated 2003.COPD. 2004;1(1):105-41; discussion 3-4.
4
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, BuistSA, Calverley P, et al. Global strategy for thediagnosis, management, and prevention ofchronic obstructive pulmonary disease: GOLDexecutive summary. Am J Respir Crit Care Med.2007;176(6):532-55.
5
5. Pesci A, Balbi B, Majori M, Cacciani G,Bertacco S, Alciato P, et al. Inflammatory cellsand mediators in bronchial lavage of patientswith chronic obstructive pulmonary disease. Eur Respir J. 1998;12(2):380-6.
6
6. Vlahos R, Bozinovski S, Chan SP, Ivanov S,Linden A, Hamilton JA, et al. Neutralizing granulocyte/macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation. Am J Respir Crit Care Med. 2010;182(1):34-40.
7
7. Betsuyaku T, Hamamura I, Hata J, TakahashiH, Mitsuhashi H, Adair-Kirk TL, et al.Bronchiolar chemokine expression is differentafter single versus repeated cigarette smokeexposure. Respir Res. 2008;9:7.
8
8. Boswell-Smith V, Spina D. PDE4 inhibitors aspotential therapeutic agents in the treatment ofCOPD-focus on roflumilast. Int J Chron ObstructPulmon Dis. 2007;2(2):121-9.
9
9. Rabe KF, Tenor H, Dent G, Schudt C, LiebigS, Magnussen H. Phosphodiesterase isozymesmodulating inherent tone in human airways:identification and characterization. Am J Physiol.1993;264(5 Pt 1):L458-64.
10
10. Hatzelmann A, Schudt C. Anti-inflammatory andimmunomodulatory potential of the novel PDE4inhibitor roflumilast in vitro. J Pharmacol ExpTher. 2001;297(1):267-79.
11
11. Kumar RK, Herbert C, Thomas PS, Wollin L,Beume R, Yang M, et al. Inhibition ofinflammation and remodeling by roflumilast anddexamethasone in murine chronic asthma. JPharmacol Exp Ther. 2003;307(1):349-55.
12
12. Raouraoua-Boukari R, Sami-Merah S, Hammoudi-Triki D, Martin-Eauclaire MF, Laraba-DjebariF. Immunomodulation of the inflammatory response induced by Androctonus australis hector neurotoxins: biomarker interactions. Neuroimmunomodulation. 2012;19(2):103-10.
13
13. George J, Ioannides-Demos LL, Santamaria NM,Kong DC, Stewart K. Use of complementary andalternative medicines by patients with chronicobstructive pulmonary disease. Med J Aust.2004;181(5):248-51.
14
14. Lee H, Lee D, Kim Y, Lee G, Kim S-J, JungS, et al. Lipopolysaccharide-induced lunginflammation is inhibited by Lonicera japonicaMol Cell Toxicol. 2011;7(1):87-93
15
15. Park E, Kum S, Wang C, Park SY, Kim BS,Schuller-Levis G. Anti-inflammatory activity ofherbal medicines: inhibition of nitric oxideproduction and tumor necrosis factor-alphasecretion in an activated macrophage-like cellline. Am J Chin Med. 2005;33(3):415-24.
16
16. Xagorari A, Papapetropoulos A, Mauromatis A,Economou M, Fotsis T, Roussos C. Luteolininhibits an endotoxin-stimulated phosphorylationcascade and proinflammatory cytokineproduction in macrophages. J Pharmacol ExpTher. 2001;296(1):181-7.
17
17. Choi JM, Ahn MH, Chae WJ, Jung YG, ParkJC, Song HM, et al. Intranasal delivery of thecytoplasmic domain of CTLA-4 using a novelprotein transduction domain prevents allergicinflammation. Nat Med. 2006;12(5):574-9.
18
18. Mannino DM, Buist AS. Global burden ofCOPD: risk factors, prevalence, and futuretrends. Lancet. 2007;370(9589):765-73.
19
19. Kim D, You B, Lim H, Lee SJ. Toll-like receptor2 contributes to chemokine gene expression andmacrophage infiltration in the dorsal root gangliaafter peripheral nerve injury. Mol Pain.2011;7:74.
20
20. Stampfli MR, Anderson GP. How cigarettesmoke skews immune responses to promoteinfection, lung disease and cancer. Nat RevImmunol. 2009;9(5):377-84.
21
21. Cosio MG, Saetta M, Agusti A. Immunologicaspects of chronic obstructive pulmonary disease.N Engl J Med. 2009;360(23):2445-54.
22
22. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol.2009;4:435-59.
23
23. Hautamaki RD, Kobayashi DK, Senior RM,Shapiro SD. Requirement for macrophageelastase for cigarette smoke-induced emphysemain mice. Science. 1997;277(5334):2002-4.
24
24. Siafakas NM, Vermeire P, Pride NB, PaolettiP, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European RespiratorySociety Task Force. Eur Respir J. 1995;8(8):1398-420.
25
25. Page CP, Spina D. Phosphodiesterase inhibitorsin the treatment of inflammatory diseases. HandbExp Pharmacol. 2011(204):391-414.
26
26. Calverley PM, Rabe KF, Goehring UM,Kristiansen S, Fabbri LM, Martinez FJ.Roflumilast in symptomatic chronic obstructivepulmonary disease: two randomised clinicaltrials. Lancet. 2009;374(9691):685-94.
27
27. Rabe KF, Bateman ED, O'Donnell D, Witte S,Bredenbroker D, Bethke TD. Roflumilast--anoral anti-inflammatory treatment for chronicobstructive pulmonary disease: a randomisedcontrolled trial. Lancet. 2005;366(9485):563-71.
28
28. Blanc PD, Trupin L, Earnest G, Katz PP, YelinEH, Eisner MD. Alternative therapies amongadults with a reported diagnosis of asthma orrhinosinusitis: data from a population-basedsurvey. Chest. 2001;120(5):1461-7.
29
29. Clark CE, Arnold E, Lasserson TJ, Wu T. Herbalinterventions for chronic asthma in adults andchildren: a systematic review and meta-analysis.Prim Care Respir J. 2010;19(4):307-14.
30
30. Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, et al. Lipopolysaccharide-induced lung inflammation is inhibited byneutralization of GM-CSF. Eur J Pharmacol. 2007;557(2-3):230-5.
31
31. Chung KF. Cytokines in chronic obstructivepulmonary disease. Eur Respir J Suppl.2001;34:50s-9s.
32
32. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology.Respir Res. 2006;7:125.
33
33. Chen CY, Peng WH, Tsai KD, Hsu SL. Luteolinsuppresses inflammation-associated geneexpression by blocking NF-kappaB and AP-1activation pathway in mouse alveolarmacrophages. Life Sci. 2007;81(23-24):1602-14.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations
Other articles from this issue
- Correlation between Abdominal Fat Distribution and Abdominal Temperature in Korean Premenopausal Obese Women
- Lonicerae Flos Inhibits Cigarette-induced Lung Inflammatory Responses in Animal Model of Chronic Obstructive Pulmonary Disease
- Screening of Preventive Effects of Herbal Prescriptions in Rat Model of Arterial Thrombosis Induced by Ferric Chloride
- Literature Review on Biological Effects of Gyejibokryeong-hwan against Gynaecological Diseases
- A Study on the Strategic Vitalization Plan of Korean Integrated Medical Tourism
- Anti-thrombotic Effects of Modified Jeho-tang using a FeCl3-induced Carotid Arterial Thrombosis Model
- Successful Treatment of Two Patients with Immune Thrombocytopenic Purpura Using Herbal Decoction
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.